EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Protara Therapeutics's enterprise value is $-28.67 Mil.
Protara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-43.27 Mil. Therefore, Protara Therapeutics's EV-to-EBITDA for today is 0.66.
The historical rank and industry rank for Protara Therapeutics's EV-to-EBITDA or its related term are showing as below:
TARA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1842535.36 Med: 0 Max: 2725380.36
Current: 0.66
During the past 6 years, the highest EV-to-EBITDA of Protara Therapeutics was 2725380.36. The lowest was -1842535.36. And the median was 0.00.
TARA's EV-to-EBITDA is ranked better than 74.84% of 469
companies
in the Biotechnology industry
Industry Median: 9.16
vs TARA: 0.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), Protara Therapeutics's stock price is $2.64.
Protara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.570. Therefore, Protara Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Protara Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Protara Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protara Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's EV-to-EBITDA falls into.
Protara Therapeutics EV-to-EBITDA Calculation
Protara Therapeutics's EV-to-EBITDA for today is calculated as:
Protara Therapeutics's current Enterprise Value is $-28.67 Mil.
Protara Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-43.27 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Protara Therapeutics's PE Ratio for today is calculated as:
Protara Therapeutics's share price for today is $2.64.
Protara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.570.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Protara Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Protara Therapeutics (Protara Therapeutics) Business Description
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TARA has been successfully added to your 